Browse > Home / Pharmacy Industry News / Abbott Wins Top Honor In Wall Street Journal Technology Innovation Awards

Abbott Wins Top Honor In Wall Street Journal Technology Innovation Awards

September 18, 2009

Abbott announced it has been named the overall Gold winner of the 2009 Wall Street Journal Technology Innovation Awards for its Ibis T5000 Biosensor regularity, what one. is designed to detect and characterize a gross range of infectious agents in a given sample, including viruses, bacteria and fungi.

“Abbott is dedicated to pursuing novelty to find meaningful solutions that improve lives,” said Stafford O’Kelly, head of Abbott’s molecular diagnostics business. “This technology represents scientific innovation at its highly best, and Abbott is honored to receive this serious award.”

Abbott’sitting Ibis system (now marketed under the PLEX-ID employment name) was singled out for the top honor, in part, because it promises to alert freedom from disease officials to new disease strains, and may moreover guard in anticipation of bioterrorism and enable hospitals to identify antibiotic-resistant bacteria in its environment.

The Wall Street Journal reports that inasmuch as the first system was completed in 2005, the technology has “been deployed in 20 sites round the U.S., including the Centers for Disease Control. This spring, the device helped the Naval Health Research Center in San Diego to identify the first two cases of the H1N1 swine flu in the U.S.”

The PLEX-ID is a high-throughput technology based in succession a combination of corpuscular technologies, including polymerase chain reaction (PCR) and congeries spectrometry analysis. The system is designed to address a signifying unmet need by providing touchstone results in six to seven hours instead of three or besides days as required with current culturing methods.

PLEX-ID is generally intended for research use only and not for use in diagnostic procedures. It is clever of identifying to all intents and purposes quite bacteria, viruses and fungi, and be able to provide information about drug resistance, poisonousness and strain type of these agents. Commercial applications for the system include epidemiologic oversight, monitoring of pandemic diseases, identification of emerging or previously unknown agents, forensic characterization of human samples, identification of sources of hospital-associated infections. Abbott is currently developing the system for human catching ail diagnostics.

Source
Abbott Laboratories

Written by Samanta · Filed Under Pharmacy Industry News